Ketamine in Bipolar Disorder: A Review

References

• Abreu LN, Lafer B, Baca-Garcia E, Oquendo MA. Suicidal ideation and suicide attempts in bipolar disorder type I: an update for the clinician. Rev Bras Psiquiatr. 2009;31:271–280. doi:10.1590/s1516-4446200900500000319787156
   PubMed Web of Science ®Google Scholar
• Jamison KR. Suicide and bipolar disorder. J Clin Psychiatry. 2000;61:47–51.
   PubMed Web of Science ®Google Scholar
• Kupka RW, Altshuler LL, Nolen WA, et al. Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord. 2007;9:531–535. doi:10.1111/j.1399-5618.2007.00467.x17680925
   PubMed Web of Science ®Google Scholar
• Hidalgo-Mazzei D, Berk M, Cipriani A, et al. Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition. Br J Psychiatry. 2019;214:27–35. doi:10.1192/bjp.2019.3630520709
   PubMed Web of Science ®Google Scholar
• Li CT, Bai YM, Huang YL, et al. Association between antidepressant resistance in unipolar depression and subsequent bipolar disorder: cohort study. Br J Psychiatry. 2012;200:45–51. doi:10.1192/bjp.bp.110.08698322016435
   PubMed Web of Science ®Google Scholar
• Tondo L, Vázquez GH, Baldessarini RJ. Options for pharmacological treatment of refractory bipolar depression. Curr Psychiatry Rep. 2014;16:431. doi:10.1007/s11920-013-0431-y24425269
   PubMed Web of Science ®Google Scholar
• Peyrovian B, McIntyre RS, Phan L, et al. Registered clinical trials investigating ketamine for psychiatric disorders. J Psychiatr Res. 2020;127:1–12. doi:10.1016/j.jpsychires.2020.03.02032315806
   PubMed Web of Science ®Google Scholar
• Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351–354. doi:10.1016/S0006-3223(99)00230-910686270
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Singh J, Manji HK. Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry. 2006;59:1006–1020.16487491
   PubMed Web of Science ®Google Scholar
• Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment resistant bipolar depression. Arch Gen Psychiatry. 2010;67:793–802. doi:10.1001/archgenpsychiatry.2010.9020679587
   PubMed Web of Science ®Google Scholar
• Zarate CA Jr, Brutsche NE, Ibrahim L, et al. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012;71:939–946. doi:10.1016/j.biopsych.2011.12.01022297150
   PubMed Web of Science ®Google Scholar
• Grunebaum MF, Ellis SP, Keip JG, et al. Ketamine versus midazolam in bipolar depression with suicidal thoughts: a pilot midazolam-controlled randomized clinical trial. Bipolar Disord. 2017;19(3):176–183. doi:10.1038/s41386-019-0317-828452409
   PubMed Web of Science ®Google Scholar
• Ionescu DF, Luckenbaugh DA, Niciu MJ, Richards EM, Zarate CA Jr. A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. Bipolar Disord. 2015;17:438–443. doi:10.1111/bdi.1227725400146
   PubMed Web of Science ®Google Scholar
• Permoda-Osip A, Skibinska M, Bartkowska-Sniatkowska A, Kliwicki S, Chlopocka-Wozniak M, Rybakowski JK. Factors connected with efficacy of single ketamine infusion in bipolar depression. Psychiatr Pol. 2014;48:35–47. doi:10.12740/PP/2117524946433
   PubMed Web of Science ®Google Scholar
• Rybakowski JK, Permoda-Osip A, Bartkowska-Sniatkowska A. Ketamine augmentation rapidly improves depression scores in inpatients with treatment-resistant bipolar depression. Int J Psychiatry Clin Pract. 2017;21:99–103. doi:10.1080/13651501.2017.129783428271731
   PubMed Web of Science ®Google Scholar
• Correia-Melo FS, Argolo FC, Araujo-de-Freitas L, et al. Rapid infusion of esketamine for unipolar and bipolar depression: a retrospective chart review. Neuropsychiatr Dis Treat. 2017;13:1627–1632. doi:10.2147/NDT.S13562328790825
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Chawia JM, Hagi K, et al. Single-dose infusion ketamine and non-ketamine N-methyl-D-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychol Med. 2016;46:1459–1472. doi:10.1017/S003329171600006426867988
   PubMed Web of Science ®Google Scholar
• Wilkinson ST, Ballard ED, Bloch MH, et al. The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. Am J Psychiatry. 2018;175:150–158. doi:10.1176/appi.ajp.2017.1704047228969441
   PubMed Web of Science ®Google Scholar
• Niciu MJ, Luckenbaugh DA, Ionescu DF, et al. Clinical predictors of ketamine response in treatment-resistant major depression. J Clin Psychiatry. 2014;75:e417–e423. doi:10.4088/JCP.13m0869824922494
   PubMed Web of Science ®Google Scholar
• Machado-Vieira R, Gold PW, Luckenbaugh DA, et al. The role of adipokines in the rapid antidepressant effects of ketamine. Mol Psychiatry. 2017;22:127–133. doi:10.1038/mp.2016.3627046644
   PubMed Web of Science ®Google Scholar
• Lara DR, Bisol LW, Munari LR. Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression. Int J Neuropsychopharmacol. 2013;16:2111–2117. doi:10.1017/S146114571300048523683309
   PubMed Web of Science ®Google Scholar
• Zheng W, Zhou YL, Liu WJ, et al. Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression. Psychiatry Res. 2018;106:61–68. doi:10.1016/j.jpsychires.2018.09.013
   Web of Science ®Google Scholar
• Zheng W, Zhou YL, Liu WJ, et al. A preliminary study of adjunctive ketamine for treatment-resistant bipolar depression. J Affect Disord. 2020;275:38–43. doi:10.1016/j.jad.2020.06.02032658821
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Rodrigues NB, Lee Y, et al. The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: results from the Canadian rapid treatment center of excellence. J Affect Disord. 2020;274:903–910. doi:10.1016/j.jad.2020.05.08832664031
   PubMed Web of Science ®Google Scholar
• McAllister-Williams RH, Arango C, Blier P, et al. The identification, assessment and management of difficult-to-treat depression: an international consensus statement. J Affect Disord. 2020;15(267):264–282. doi:10.1016/j.jad.2020.02.023
   Web of Science ®Google Scholar
• McIntyre RS, Lipsitz O, Rodrigues NB, et al. The effectiveness of ketamine on anxiety, irritability, and agitation: implications for treating mixed features in adults with major depressive or bipolar disorder. Bipolar Disord. 2020. doi:10.1111/bdi.12941
   Web of Science ®Google Scholar
• Shim IH, Lee J, Kim MD, et al. The prevalence and diagnostic classification of mixed features in patients with major depressive episodes: a multicenter study based on the DSM-5. Int J Methods Psychiatr Res. 2019;28(3):e1773. doi:10.1002/mpr.177330786322
   PubMed Web of Science ®Google Scholar
• Schaffer A, Isometsä ET, Tondo L, et al. International society for bipolar disorders task force on suicide: metaanalyses and meta-regression of correlates of suicide attempts and suicide deaths in bipolar disorder. Bipolar Disord. 2015;17:1–16. doi:10.1111/bdi.12271
   PubMed Web of Science ®Google Scholar
• Carter TD, Mundo E, Parikh SV, Kennedy JL. Early age at onset as a risk factor for poor outcome of bipolar disorder. J Psychiatr Res. 2003;37:297–303. doi:10.1016/S0022-3956(03)00052-912765852
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Pompili M, Tondo L. Suicide in bipolar disorder: risks and management. CNS Spectr. 2006;11(6):465–471. doi:10.1017/S109285290001468116816785
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Tondo L, Vázquez GH. Pharmacological treatment of adult bipolar disorder. Mol Psychiatry. 2019;24(2):198–217. doi:10.1038/s41380-018-0044-229679069
   PubMed Web of Science ®Google Scholar
• Price RB, Nock MK, Charney DS, et al. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry. 2009;66:522–526. doi:10.1016/j.biopsych.2009.04.02919545857
   PubMed Web of Science ®Google Scholar
• DiazGranados N, Ibrahim LA, Brutsche NE, et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry. 2010;71:1605–1611. doi:10.4088/JCP.09m05327blu20673547
   PubMed Web of Science ®Google Scholar
• Ballard ED, Ionescu DF, Vande Voort JL, et al. Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. J Psychiatr Res. 2014;58:161–166. doi:10.1016/j.jpsychires.2014.07.02725169854
   PubMed Web of Science ®Google Scholar
• Bartoli F, Riboldi I, Crocamo C, Di Brita C, Clerici M, Carrà G. Ketamine as a rapid-acting agent for suicidal ideation: a meta-analysis. Neurosci Biobehav Rev. 2017;77:232–236. doi:10.1016/j.neubiorev.2017.03.01028342764
   PubMed Web of Science ®Google Scholar
• Zhan Y, Zhang B, Zhou Y, et al. A preliminary study of anti-suicidal efficacy of repeated ketamine infusions in depression with suicidal ideation. J Affect Disord. 2019;15(251):205–212. doi:10.1016/j.jad.2019.03.071
   Web of Science ®Google Scholar
• Sublette ME, Galfalvy HC, Fuchs D, et al. Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder. Brain Behav Immun. 2011;25:1272–1278. doi:10.1016/j.bbi.2011.05.00221605657
   PubMed Web of Science ®Google Scholar
• Bay-Richter C, Linderholm KR, Lim CK, et al. A role for inflammatory metabolites as modulators of the glutamate N-methyl-D-aspartate receptor in depression and suicidality. Brain Behav Immun. 2015;43:110–117. doi:10.1016/j.bbi.2014.07.01225124710
   PubMed Web of Science ®Google Scholar
• Steiner J, Bielau H, Brisch R, et al. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res. 2008;42:151–157. doi:10.1016/j.jpsychires.2006.10.01317174336
   PubMed Web of Science ®Google Scholar
• Verdonk F, Petit AC, Abdel-Ahad P, et al. Microglial production of quinolinic acid as a target and a biomarker of the antidepressant effect of ketamine. Brain Behav Immun. 2019;81:361–373. doi:10.1016/j.bbi.2019.06.03331255681
   PubMed Web of Science ®Google Scholar
• Allen ND, Rodysill BR, Bostwick JM. A report of affective switching associated with ketamine: the case of ketamine-induced mania is not closed. Bipolar Disord. 2019;21(2):176–178. doi:10.1111/bdi.1272830452105
   PubMed Web of Science ®Google Scholar
• Salvadore G, Quiroz JA, Machado-Vieira R, Henter ID, Manji HK, Zarate CA Jr. The neurobiology of the switch process in bipolar disorder: a review. J Clin Psychiatry. 2010;71(11):1488–1501. doi:10.4088/JCP.09r05259gre20492846
   PubMed Web of Science ®Google Scholar
• Niciu MJ, Luckenbaugh DA, Ionescu DF, Mathews DC, Richards EM, Zarate CA Jr. Subanesthetic dose ketamine does not induce an affective switch in three independent samples of treatment-resistant major depression. Biol Psychiatry. 2013;74(10):e23–e24. doi:10.1016/j.biopsych.2013.01.03823726512
   PubMed Web of Science ®Google Scholar
• Yang C, Yang J, Luo A, Hashimoto K. Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites. Transl Psychiatry. 2019;9(1):280. doi:10.1038/s41398-019-0624-131699965
   PubMed Web of Science ®Google Scholar
• Maeng S, Zarate CA, Du J, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry. 2008;63:349–352. doi:10.1016/j.biopsych.2007.05.02817643398
   PubMed Web of Science ®Google Scholar
• Réus GZ, Stringari RB, Ribeiro KF, et al. Ketamine plus imipramine treatment induces antidepressant- like behavior and increases CREB and BDNF protein levels and PKA and PKC phosphorylation in rat brain. Behav Brain Res. 2011;221(1):166–171. doi:10.1016/j.bbr.2011.02.02421397634
   PubMed Web of Science ®Google Scholar
• Wei Z, Zhang K, Zhou Q, et al. Differential mechanisms underlying antidepressant responses of ketamine and imipramine. CNS Neurol Disord Drug Targets. 2017;16(7):846–853. doi:10.2174/187152731666617042812324828462695
   PubMed Web of Science ®Google Scholar
• Zanos P, Moaddel R, Morris PJ, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016;533(7604):481–486. doi:10.1038/nature1799827144355
   PubMed Web of Science ®Google Scholar
• Freund N, Juckel G. Bipolar disorder: its etiology and how to model in rodents. Methods Mol Biol. 2019;2011:61–77. doi:10.1007/978-1-4939-9554-7_431273693
   PubMedGoogle Scholar
• Maletic V, Raison C. Integrated neurobiology of bipolar disorder. Front Psychiatry. 2014;5:98. doi:10.3389/fpsyt.2014.0009825202283
   PubMed Web of Science ®Google Scholar
• Grande I, Fries GR, Kunz M, Kapczinski F. The role of BDNF as a mediator of neuroplasticity in bipolar disorder. Psychiatry Investig. 2010;7:243–250. doi:10.4306/pi.2010.7.4.243
   PubMed Web of Science ®Google Scholar
• Faraguna U, Vyazovskiy VV, Nelson AB, Tononi G, Cirelli C. A causal role for brain-derived neurotrophic factor in the homeostatic regulation of sleep. J Neurosci. 2008;28:4088–4095. doi:10.1523/JNEUROSCI.5510-07.200818400908
   PubMed Web of Science ®Google Scholar
• Shaltiel G, Chen G, Manji HK. Neurotrophic signalling cascades in the patho-physiology and treatment of bipolar disorder. CurrOpinPharmacol. 2007;7:22–26. doi:10.1016/j.coph.2006.07.005
   Web of Science ®Google Scholar
• Cunha AB, Frey BN, Andreazza AC, et al. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. NeurosciLett. 2006;398:215–219. doi:10.1016/j.neulet.2005.12.085
   PubMed Web of Science ®Google Scholar
• Machado-Vieira R, Dietrich MO, Leke R, et al. Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episode. BiolPsychiatry. 2007;61:142–144. doi:10.1016/j.biopsych.2006.03.070
   Web of Science ®Google Scholar
• Yang C, Shirayama Y, Zhang J-C, et al. R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry. 2015;5:e632. doi:10.1038/tp.2015.13626327690
   PubMed Web of Science ®Google Scholar
• Dong C, Zhang JC, Yao W, et al. Rapid and sustained antidepressant action of the mGlu2/3 receptor antagonist MGS0039 in the social defeat stress model: comparison with ketamine. Int J Neuropsychopharmacol. 2017;20:228–236.27765808
   PubMed Web of Science ®Google Scholar
• Moda-Sava RN, Murdock MH, Parekh PK, et al. Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation. Science. 2019;364:pii: eaat8078.
   Web of Science ®Google Scholar
• Ma Z, Zang T, Birnbaum SG, et al. TrkB dependent adult hippocampal progenitor differentiation mediates sustained ketamine antidepressant response. Nat Commun. 2017;8(1):1668. doi:10.1038/s41467-017-01709-829162814
   PubMed Web of Science ®Google Scholar
• Soumier A, Carter RM, Schoenfeld TJ, Cameron HA. New hippocampal neurons mature rapidly in response to ketamine but are not required for its acute antidepressant effects on neophagia in rats. eNeuro. 2016;3(2). doi:10.1523/ENEURO.0116-15.2016
   Google Scholar
• Yamada J, Jinno S. Potential link between antidepressant-like effects of ketamine and promotion of adult neurogenesis in the ventral hippocampus of mice. Neuropharmacology. 2019;158:107710. doi:10.1016/j.neuropharm.2019.10771031310776
   PubMed Web of Science ®Google Scholar
• Choi M, Lee SH, Chang HL, Son H. Hippocampal VEGF is necessary for antidepressant-like behaviors but not sufficient for antidepressant-like effects of ketamine in rats. Biochim Biophys Acta. 2016;1862(7):1247–1254. doi:10.1016/j.bbadis.2016.04.00127063455
   PubMed Web of Science ®Google Scholar
• Michaelsson H, Andersson M, Svensson J, et al. The novel antidepressant ketamine enhances dentate gyrus proliferation with no effects on synaptic plasticity or hippocampal function in depressive-like rats. Acta Physiol. 2019;225(4):e13211. doi:10.1111/apha.13211
   Web of Science ®Google Scholar
• Ludwig B, Dwivedi Y. Dissecting bipolar disorder complexity through epigenomic approach. Mol Psychiatry. 2016;21:1490–1498.27480490
   PubMed Web of Science ®Google Scholar
• Machado-Vieira R, Ibrahim L, Zarate CA Jr. Histone deacetylases and mood disorders: epigenetic programming in gene-environment interactions. CNS Neurosci Ther. 2011;17:699–704. doi:10.1111/j.1755-5949.2010.00203.x20961400
   PubMed Web of Science ®Google Scholar
• Hobara T, Uchida S, Otsuki K, et al. Altered gene expression of histone deacetylases in mood disorder patients. J Psychiatr Res. 2010;44:263–270. doi:10.1016/j.jpsychires.2009.08.01519767015
   PubMed Web of Science ®Google Scholar
• Munkholm K, Vinberg M, Berk M, Kessing LV. State-related alterations of gene expression in bipolar disorder: a systematic review. Bipolar Disord. 2012;14:684–696. doi:10.1111/bdi.1200523043691
   PubMed Web of Science ®Google Scholar
• Soeiro-de-Souza MG, Andreazza AC, Carvalho AF, Machado-Vieira R, Young LT, Moreno RA. Number of manic episodes is associated with elevated DNA oxidation in bipolar I disorder. Int J Neuropsychopharmacol. 2013;16:1505–1512. doi:10.1017/S146114571300004723449001
   PubMed Web of Science ®Google Scholar
• Abdolmaleky HM, Cheng KH, Faraone SV, et al. Hypomethylation of MB-COMT promoter is a major risk factor for Schizophrenia and bipolar disorder. Hum Mol Genet. 2006;15:3132–3145. doi:10.1093/hmg/ddl25316984965
   PubMed Web of Science ®Google Scholar
• Réus GZ, Abelaira HM, Dos Santos MA, et al. Ketamine and imipramine in the nucleus accumbens regulate histone deacetylation induced by maternal deprivation and are critical for associated behaviors. Behav Brain Res. 2013;256:451–456. doi:10.1016/j.bbr.2013.08.04124004850
   PubMed Web of Science ®Google Scholar
• Modabbernia A, Taslimi S, Brietzke E, Ashrafi M. Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry. 2013;74(1):15–25. doi:10.1016/j.biopsych.2013.01.00723419545
   PubMed Web of Science ®Google Scholar
• Wang AK, Miller BJ. Meta-analysis of cerebrospinal fluid cytokine and tryptophan catabolite alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder, and depression. Schizophr Bull. 2018;44(1):75–83. doi:10.1093/schbul/sbx03528338954
   PubMed Web of Science ®Google Scholar
• Rao JS, Harry GJ, Rapoport SI, Kim HW. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol Psychiatry. 2010;15(4):384–392. doi:10.1038/mp.2009.4719488045
   PubMed Web of Science ®Google Scholar
• Perugi G, Quaranta G, Belletti S, et al. General medical conditions in 347 bipolar disorder patients: clinical correlates of metabolic and autoimmune-allergic diseases. J Affect Disord. 2015;170:95–103. doi:10.1016/j.jad.2014.08.05225237732
   PubMed Web of Science ®Google Scholar
• Kiraly DD, Horn SR, Van Dam NT, et al. Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome. Transl Psychiatry. 2017;7:e1065. doi:10.1038/tp.2017.3128323284
   PubMed Web of Science ®Google Scholar
• Chen MH, Li CT, Lin WC, et al. Rapid inflammation modulation and antidepressant efficacy of a low-dose ketamine infusion in treatment-resistant depression: a randomized, double-blind control study. Psychiatry Res. 2018;269:207–211. doi:10.1016/j.psychres.2018.08.07830153598
   PubMed Web of Science ®Google Scholar
• Kadriu B, Farmer CA, Yuan P, et al. The kynurenine pathway and bipolar disorder: intersection of the monoaminergic and glutamatergic systems and immune response. Mol Psychiatry. 2019. doi:10.1038/s41380-019-0589-8
   Web of Science ®Google Scholar
• Lee JE, Lee JM, Park YJ, et al. Inhibition of autoimmune Th17 cell responses by pain killer ketamine. Oncotarget. 2017;8(52):89475–89485. doi:10.18632/oncotarget.1832429163764
   PubMedGoogle Scholar
• Zheng P, Zeng B, Zhou C, et al. Gut microbiome remodelling induces depressive-like behaviors through a pathway mediated by the host’s metabolism. Mol Psychiatry. 2016;21:786–796.27067014
   PubMed Web of Science ®Google Scholar
• Macedo D, Filho AJ, de Sousa CNS, Quevedo J, Barichello T Jr, Freitas de Lucena D. Antidepressants, antimicrobials or both? Gut microbiota dysbiosis in depression and possible implications of the antimicrobial effects of antidepressant drugs for antidepressant effectiveness. J Affect Disord. 2017;208:22–32.27744123
   PubMed Web of Science ®Google Scholar
• Getachew B, Aubee JI, Schottenfeld RS, Csoka AB, Thompson KM, Tizabi Y. Ketamine interactions with gut-microbiota in rats: relevance to its antidepressant and anti-inflammatory properties. BMC Microbiol. 2018;18:222.30579332
   PubMed Web of Science ®Google Scholar
• Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol. 2009;6:306–314. doi:10.1038/nrgastro.2009.3519404271
   PubMed Web of Science ®Google Scholar
• El Aidy S, Dinan TG, Cryan JF. Gut microbiota: the conductor in the orchestra of immune-neuroendocrine communication. Clin Ther. 2015;37:954–967. doi:10.1016/j.clinthera.2015.03.00225846319
   PubMed Web of Science ®Google Scholar
• Bercik P, Collins SM, Verdu EF. Microbes and the gut–brain axis. Neurogastroenterol Motil. 2012;24(5):405–413.22404222
   PubMed Web of Science ®Google Scholar
• Maqsood R, Stone TW. the gut-brain axis, BDNF, NMDA and CNS disorders. Neurochem Res. 2016;41(11):2819–2835.27553784
   PubMed Web of Science ®Google Scholar
• Lu Q, Lai J, Lu H, et al. Gut microbiota in bipolar depression and its relationship to brain function: an advanced exploration. Front Psychiatry. 2019;29;10:784. doi:10.3389/fpsyt.2019.00784
   Web of Science ®Google Scholar
• Aizawa E, Tsuji H, Asahara T, et al. Bifidobacterium and lactobacillus counts in the gut microbiota of patients with bipolar disorder and healthy controls. Front Psychiatry. 2018;9:730. doi:10.3389/fpsyt.2018.0073030713509
   PubMed Web of Science ®Google Scholar
• Qu Y, Yang C, Ren Q, Ma M, Dong C, Hashimoto K. Comparison of (R)-ketamine and lanicemine on depression-like phenotype and abnormal composition of gut microbiota in a social defeat stress model. Sci Rep. 2017;7:15725.29147024
   PubMed Web of Science ®Google Scholar
• Yang C, Qu Y, Fujita Y, et al. Possible role of gut-microbiota in the antidepressant effects of (R)-ketamine in a social defeat stress model. Transl Psychiatry. 2017;7:1294.29249803
   PubMed Web of Science ®Google Scholar
• Huang N, Hua D, Zhan G, et al. Role of Actinobacteria and Coriobacteriia in the antidepressant effects of ketamine in an inflammation model of depression. Pharmacol Biochem Behav. 2018;176:93–100.30528936
   PubMed Web of Science ®Google Scholar
• Cui H, Meng Y, Bulleit RF. Inhibition of glycogen synthase kinase 3beta activity regulates proliferation of cultured cerebellar granule cells. Brain Res Dev Brain Res. 1998;111(2):177–188.9838099
   PubMedGoogle Scholar
• Gould TD, Chen G, Manji HK. In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology. 2004;29(1):32–38.12942141
   PubMed Web of Science ®Google Scholar
• Polter A, Beurel E, Yang S, et al. Deficiency in the inhibitory serine-phosphorylation of glycogen synthase kinase-3 increases sensitivity to mood disturbances. Neuropsychopharmacology. 2010;35(8):1761–1774.20357757
   PubMed Web of Science ®Google Scholar
• Costemale-Lacoste JF, Guilloux JP, Gaillard R. The role of GSK-3 in treatment-resistant depression and links with the pharmacological effects of lithium and ketamine: a review of the literature. Encephale. 2016;42(2):156–164.26995153
   PubMed Web of Science ®Google Scholar
• Jope RS. Anti-bipolar therapy: mechanism of action of lithium. Mol Psychiatry. 1999;4(2):117–128.10208444
   PubMed Web of Science ®Google Scholar
• Chiu CT, Scheuing L, Liu G, et al. The mood stabilizer lithium potentiates the antidepressant-like effects and ameliorates oxidative stress induced by acute ketamine in a mouse model of stress. Int J Neuropsychopharmacol. 2014;18:pyu102.25548109
   PubMed Web of Science ®Google Scholar
• Leu SJ, Yang YY, Liu HC, et al. Valproic acid and lithium meditate anti-inflammatory effects by differentially modulating dendritic cell differentiation and function. J Cell Physiol. 2017;232(5):1176–1186.27639185
   PubMed Web of Science ®Google Scholar
• Knijff EM, Breunis MN, Kupka RW, et al. An imbalance in the production of IL-1beta and IL-6 by monocytes of bipolar patients: restoration by lithium treatment. Bipolar Disord. 2007;9(7):743–753. doi:10.1111/j.1399-5618.2007.00444.x17988365
   PubMed Web of Science ®Google Scholar
• Vieta E, Salagre E, Grande I, et al. Early intervention in bipolar disorder. Am J Psychiatry. 2018;175(5):411–426. doi:10.1176/appi.ajp.2017.1709097229361850
   PubMed Web of Science ®Google Scholar
• de la Fuente-tomás L, Sierra P, Sanchez-Autet M, et al. A clinical staging model for bipolar disorder: longitudinal approach. Transl Psychiatry. 2020;10:45. doi:10.1038/s41398-020-0718-932066710
   PubMed Web of Science ®Google Scholar
• Berk M, Conus P, Lucas N, et al. Setting the stage: from prodrome to treatment resistance in bipolar disorder. Bipolar Disord. 2007;9(7):671–678. doi:10.1111/j.1399-5618.2007.0048417988356
   PubMed Web of Science ®Google Scholar
• Kapczinski F, Dias VV, Kauer-Sant’Anna M, et al. Clinical implications of a staging model for bipolar disorders. Expert Rev Neurother. 2009;9:957–966. doi:10.1586/ern.09.3119589046
   PubMed Web of Science ®Google Scholar
• Kapczinski F, Dias VV, Kauer-Sant’Anna M, et al. The potential use of biomarkers as an adjunctive tool for staging bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:1366–1371. doi:10.1016/j.pnpbp.2009.07.02719666076
   PubMed Web of Science ®Google Scholar
• Cosci F, Fava GA. Staging of mental disorders: systematic review. Psychother Psychosom. 2013;82(1):20–34. doi:10.1159/00034224323147126
   PubMed Web of Science ®Google Scholar
• Duffy A. Toward a comprehensive clinical staging model for bipolar disorder: integrating the evidence. Can J Psychiatry. 2014;59(12):659–666. doi:10.1177/07067437140590120825702367
   PubMed Web of Science ®Google Scholar
• Passos IC, Mwangi B, Vieta E, Berk M, Kapczinski F. Areas of controversy in neuroprogression in bipolar disorder. Acta Psychiatr Scand. 2016;134:91–103. doi:10.1111/acps.1258127097559
   PubMed Web of Science ®Google Scholar
• Suh JS, Schneider MA, Minuzzi L, et al. Cortical thickness in major depressive disorder: a systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2019;88:287–302. doi:10.1016/j.pnpbp.2018.08.00830118825
   PubMed Web of Science ®Google Scholar
• Syan SK, Smith M, Frey BN, et al. Resting-state functional connectivity in individuals with bipolar disorder during clinical remission: a systematic review. J Psychiatry Neurosci. 2018;43:298–316. doi:10.1503/jpn.17017530125243
   PubMed Web of Science ®Google Scholar
• Fries GR, Bauer IE, Scaini G, et al. Accelerated epigenetic aging and mitochondrial DNA copy number in bipolar disorder. Transl Psychiatry. 2017;7:1283. doi:10.1038/s41398-017-0048-829225347
   PubMed Web of Science ®Google Scholar
• Maurya PK, Noto C, Rizzo LB, et al. The role of oxidative and nitrosative stress in accelerated aging and major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2016;65:134–144. doi:10.1016/j.pnpbp.2015.08.01626348786
   PubMed Web of Science ®Google Scholar
• Gama CS, Kunz M, Magalhães PV, Kapczinski F. Staging and neuroprogression in bipolar disorder: a systematic review of the literature. Braz J Psychiatry. 2013;35:70–74. doi:10.1016/j.rbp.2012.09.00123567604
   PubMed Web of Science ®Google Scholar
• Fries GR, Pfaffenseller B, Stertz L, et al. Staging and neuroprogression in bipolar disorder. Curr Psychiatry Rep. 2012;14:667–675. doi:10.1007/s11920-012-0319-223090632
   PubMed Web of Science ®Google Scholar
• Berk M, Kapczinski F, Andreazza AC, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev. 2011;35:804–817. doi:10.1016/j.neubiorev.2010.10.00120934453
   PubMed Web of Science ®Google Scholar
• Kamintsky L, Cairns KA, Veksler R, et al. Blood-brain barrier imaging as a potential biomarker for bipolar disorder progression. Neuroimage Clin. 2020;26:102049. doi:10.1016/j.nicl.2019.10204931718955
   PubMed Web of Science ®Google Scholar
• Calkin CV. Insulin resistance takes center stage: a new paradigm in the progression of bipolar disorder. Ann Med. 2019;51(5–6):281–293. doi:10.1080/07853890.2019.165951131453713
   PubMed Web of Science ®Google Scholar
• Grande I, Magalhaes PV, Kunz M, Vieta E, Kapczinski F. Mediators of allostasis and systemic toxicity in bipolar disorder. Physiol Behav. 2012;106:46–50. doi:10.1016/j.physbeh.2011.10.02922079584
   PubMed Web of Science ®Google Scholar
• Kapczinski F, Vieta E, Andreazza AC, et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci Biobehav Rev. 2008;32:675–692. doi:10.1016/j.neubiorev.2007.10.00518199480
   PubMed Web of Science ®Google Scholar
• Yatham LN, Kapczinski F, Andreazza AC, Trevor Young L, Lam RW, Kauer-Sant’anna M. Accelerated age-related decrease in brain-derived neurotrophic factor levels in bipolar disorder. Int J Neuropsychopharmacol. 2009;12:137–139. doi:10.1017/S146114570800944918845016
   PubMed Web of Science ®Google Scholar
• Permoda-Osip A, Kisielewski J, Bartkowska-Sniatkowska A, Rybakowski JK. Single ketamine infusion and neurocognitive performance in bipolar depression. Pharmacopsychiatry. 2015;48(2):78–79. doi:10.1055/s-0034-139439925347227
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zheng W, Liu W, et al. Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression. J Psychopharmacol. 2018;32(10):1118–1126. doi:10.1177/026988111879861430260273
   PubMed Web of Science ®Google Scholar
• Hennen J, Baldessarini RJ. Reduced suicidal risk during treatment with clozapine: meta-analysis. Schizophre Res. 2005;73:139–145. doi:10.1016/j.schres.2004.05.015
   PubMed Web of Science ®Google Scholar